

Supplementary Materials for Consolidated Financial Results for Fiscal Year 2010. 12



CHUGAI PHARMACEUTICAL CO., LTD.



A member of the Roche group

- Notes: 1. Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.
2. Amounts shown in Financial Highlights, Extraordinary Gains and Losses, Statements of Revenues, Balance Sheets, Cash Flows and Capital Expenditures etc. of this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.
3. Exchange rates used for each period are as follows.

(Yen)

Fx rates	FY2007	FY2008	FY2009				FY2010				Forecast
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	FY2011
	(Full-year)	(Full-year)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(YTD)	(Full-year)
	average	average	average	average	average	average	average	average	average	average	forecast
CHF	98.13	95.54	81.55	84.52	85.68	86.20	85.80	84.42	84.00	84.17	85.00
EUR	161.17	151.38	122.06	127.19	129.32	130.10	125.58	121.21	117.66	116.32	110.00
USD	117.80	103.44	93.51	95.46	94.87	93.60	90.69	91.41	89.56	87.81	85.00
GBP	235.66	189.85	134.34	142.14	145.77	145.99	141.62	139.45	137.32	135.65	131.00

Financial Highlights (YTD)

(Billions of Yen)

	FY2007	FY2008	FY2009				FY2010								Forecasts			
			FY2009				FY2010								FY2011			
			1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)	1-6	Change (%)	1-12	Change (%)
			YTD	YTD	YTD	YTD	YTD		YTD		YTD		YTD		Half-year		Full-year	
Revenues	344.8	326.9	94.7	191.7	309.7	428.9	87.1	-8.0	182.4	-4.9	276.1	-10.8	379.5	-11.5	190.0	+4.2	403.0	+6.2
Sales	332.9	321.8	92.9	185.9	303.4	419.1	86.2	-7.2	180.6	-2.9	273.3	-9.9	375.6	-10.4	182.5	+1.1	391.7	+4.3
excl. Tamiflu	294.3	313.4	72.5	160.6	247.6	342.9	75.4	+4.0	168.6	+5.0	257.4	+4.0	357.4	+4.2	176.8	+4.9	379.5	+6.2
Tamiflu	38.7	8.4	20.4	25.4	55.8	76.2	10.8	-47.1	12.0	-52.8	15.8	-71.7	18.2	-76.1	5.7	-52.5	12.2	-33.0
Ordinary sales	10.2	7.1	6.0	11.0	18.5	36.2	1.4	-76.7	1.4	-87.3	1.4	-92.4	1.6	-95.6	5.3	+278.6	7.8	+387.5
Govt. stockpile etc.	28.5	1.3	14.4	14.4	37.3	40.0	9.5	-34.0	10.6	-26.4	14.4	-61.4	16.6	-58.5	0.4	-96.2	4.4	-73.5
Other operating revenues	11.9	5.1	1.8	5.7	6.3	9.8	0.9	-50.0	1.7	-70.2	2.8	-55.6	3.9	-60.2	7.5	+341.2	11.3	+189.7
Cost of sales	137.3	127.0	43.7	83.9	143.3	192.9	41.1	-5.9	80.5	-4.1	119.6	-16.5	162.4	-15.8	-	-	167.8	+3.3
(% of Sales)	41.2	39.5	47.0	45.1	47.2	46.0	47.7	-	44.6	-	43.8	-	43.2	-	-	-	42.8	-
Gross profit	207.5	199.9	51.0	107.8	166.4	236.1	46.0	-9.8	101.8	-5.6	156.5	-5.9	217.1	-8.0	-	-	235.2	+8.3
(% of Revenues)	60.2	61.2	53.9	56.2	53.7	55.0	52.8	-	55.8	-	56.7	-	57.2	-	-	-	58.4	-
SG&A (excl. R&D) expenses	86.6	95.1	21.6	46.1	69.8	98.2	22.8	+5.6	47.7	+3.5	71.4	+2.3	96.2	-2.0	-	-	101.0	+5.0
(% of Revenues)	25.1	29.1	22.8	24.0	22.5	22.9	26.2	-	26.2	-	25.9	-	25.3	-	-	-	25.1	-
R&D expenses	54.2	53.2	11.8	24.5	37.8	55.3	12.2	+3.4	26.6	+8.6	39.9	+5.6	54.7	-1.1	-	-	59.2	+8.2
(% of Revenues)	15.7	16.3	12.5	12.8	12.2	12.9	14.0	-	14.6	-	14.5	-	14.4	-	-	-	14.7	-
Operating income	66.7	51.6	17.5	37.2	58.8	82.6	11.1	-36.6	27.6	-25.8	45.1	-23.3	66.2	-19.9	34.0	+23.2	75.0	+13.3
(% of Revenues)	19.3	15.8	18.5	19.4	19.0	19.3	12.7	-	15.1	-	16.3	-	17.4	-	17.9	-	18.6	-
Non-operating income	4.3	9.9	5.4	6.9	7.8	9.4	1.3	-75.9	3.0	-56.5	2.2	-71.8	2.4	-74.5	-	-	-	-
Non-operating expenses	3.3	4.2	0.2	0.6	0.5	1.6	0.3	+50.0	4.4	+633.3	3.0	+500.0	3.5	+118.8	-	-	-	-
Recurring profit	67.7	57.3	22.8	43.5	66.0	90.4	12.1	-46.9	26.2	-39.8	44.3	-32.9	65.1	-28.0	34.5	+31.7	75.5	+16.0
(% of Revenues)	19.6	17.5	24.1	22.7	21.3	21.1	13.9	-	14.4	-	16.0	-	17.2	-	18.2	-	18.7	-
Extraordinary gain	0.3	7.3	0.3	0.3	0.3	0.3	0.1	-66.7	0.1	-66.7	0.1	-66.7	0.6	+100.0	-	-	-	-
Extraordinary loss	1.6	1.4	0.0	0.1	0.1	1.3	0.0	-	0.1	+0.0	0.1	+0.0	0.0	-100.0	-	-	-	-
Income before income taxes etc.	66.4	63.1	23.1	43.7	66.3	89.4	12.1	-47.6	26.1	-40.3	44.3	-33.2	65.7	-26.5	-	-	-	-
(% of Revenues)	19.3	19.3	24.4	22.8	21.4	20.8	13.9	-	14.3	-	16.0	-	17.3	-	-	-	-	-
Net income	40.1	39.3	13.8	26.3	40.9	56.6	7.9	-42.8	16.4	-37.6	28.1	-31.3	41.4	-26.9	17.0	+3.7	42.5	+2.7
(% of Revenues)	11.6	12.0	14.6	13.7	13.2	13.2	9.1	-	9.0	-	10.2	-	10.9	-	8.9	-	10.5	-

Extraordinary Gains and Losses

Extraordinary Gains

(Billions of Yen)

	Amount	Description
Restructuring and liquidation gains	0.5	This is mainly arising from the expenses that the Company expected to incur in connection with closing down Kamakura Plant for the restructuring of manufacturing function were lower than originally expected.

Financial Highlights (QTR)

(Billions of Yen)

(Billions of Yen)

															Forecasts			
	FY2007	FY2008	FY2009				FY2010								FY2011			
	1-12	1-12	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)	1-6	Change (%)	7-12	Change (%)
	Full-year	Full-year	QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR		1st Half		2nd Half	
Revenues	344.8	326.9	94.7	97.0	118.0	119.2	87.1	-8.0	95.3	-1.8	93.7	-20.6	103.4	-13.3	190.0	+4.2	213.0	+8.1
Sales	332.9	321.8	92.9	93.0	117.5	115.7	86.2	-7.2	94.5	+1.6	92.6	-21.2	102.3	-11.6	182.5	+1.1	209.2	+7.3
excl. Tamiflu	294.3	313.4	72.5	88.1	87.0	95.3	75.4	+4.0	93.3	+5.9	88.8	+2.1	100.0	+4.9	176.8	+4.9	202.7	+7.4
Tamiflu	38.7	8.4	20.4	5.0	30.4	20.4	10.8	-47.1	1.2	-76.0	3.8	-87.5	2.3	-88.7	5.7	-52.5	6.5	+6.6
Ordinary sales	10.2	7.1	6.0	5.0	7.6	17.7	1.4	-76.7	0.0	-100.0	0.0	-100.0	0.2	-98.9	5.3	+278.6	2.5	+1,150.0
Govt. stockpile etc.	28.5	1.3	14.4	-	22.9	2.7	9.5	-34.0	1.2	-	3.8	-83.4	2.1	-22.2	0.4	-96.2	4.0	-32.2
Other operating revenues	11.9	5.1	1.8	4.0	0.5	3.6	0.9	-50.0	0.8	-80.0	1.1	+120.0	1.1	-69.4	7.5	+341.2	3.8	+72.7
Cost of sales	137.3	127.0	43.7	40.1	59.4	49.5	41.1	-5.9	39.5	-1.5	39.1	-34.2	42.8	-13.5	-	-	-	-
(% of Sales)	41.2	39.5	47.0	43.1	50.6	42.8	47.7	-	41.8	-	42.2	-	41.8	-	-	-	-	-
Gross profit	207.5	199.9	51.0	56.9	58.6	69.7	46.0	-9.8	55.8	-1.9	54.6	-6.8	60.6	-13.1	-	-	-	-
(% of Revenues)	60.2	61.2	53.9	58.7	49.7	58.5	52.8	-	58.6	-	58.3	-	58.6	-	-	-	-	-
SG&A (excl. R&D) expenses	86.6	95.1	21.6	24.5	23.7	28.3	22.8	+5.6	24.9	+1.6	23.7	+0.0	24.7	-12.7	-	-	-	-
(% of Revenues)	25.1	29.1	22.8	25.3	20.1	23.7	26.2	-	26.1	-	25.3	-	23.9	-	-	-	-	-
R&D expenses	54.2	53.2	11.8	12.7	13.3	17.5	12.2	+3.4	14.4	+13.4	13.3	+0.0	14.8	-15.4	-	-	-	-
(% of Revenues)	15.7	16.3	12.5	13.1	11.3	14.7	14.0	-	15.1	-	14.2	-	14.3	-	-	-	-	-
Operating income	66.7	51.6	17.5	19.6	21.6	23.8	11.1	-36.6	16.5	-15.8	17.6	-18.5	21.1	-11.3	34.0	+23.2	41.0	+5.9
(% of Revenues)	19.3	15.8	18.5	20.2	18.3	20.0	12.7	-	17.3	-	18.8	-	20.4	-	17.9	-	19.2	-
Non-operating income	4.3	9.9	5.4	1.5	1.2	1.7	1.3	-75.9	1.7	+13.3	1.6	+33.3	0.5	-70.6	-	-	-	-
Non-operating expenses	3.3	4.2	0.2	0.5	0.2	1.1	0.3	+50.0	4.1	+720.0	1.1	+450.0	0.7	-36.4	-	-	-	-
Recurring profit	67.7	57.3	22.8	20.7	22.6	24.4	12.1	-46.9	14.1	-31.9	18.1	-19.9	20.8	-14.8	34.5	+31.7	41.0	+5.4
(% of Revenues)	19.6	17.5	24.1	21.3	19.2	20.5	13.9	-	14.8	-	19.3	-	20.1	-	18.2	-	19.2	-
Extraordinary gain	0.3	7.3	0.3	-	0.0	-	0.1	-66.7	-	-	0.1	-	0.6	-	-	-	-	-
Extraordinary loss	1.6	1.4	0.0	0.0	0.0	1.2	0.0	-	0.0	-	0.0	-	0.0	-100.0	-	-	-	-
Income before income taxes etc.	66.4	63.1	23.1	20.6	22.6	23.2	12.1	-47.6	14.1	-31.6	18.2	-19.5	21.4	-7.8	-	-	-	-
(% of Revenues)	19.3	19.3	24.4	21.2	19.2	19.5	13.9	-	14.8	-	19.4	-	20.7	-	-	-	-	-
Net income	40.1	39.3	13.8	12.5	14.6	15.7	7.9	-42.8	8.5	-32.0	11.7	-19.9	13.4	-14.6	17.0	+3.7	25.5	+1.6
(% of Revenues)	11.6	12.0	14.6	12.9	12.4	13.2	9.1	-	8.9	-	12.5	-	13.0	-	8.9	-	12.0	-

Statements of Revenues (YTD)

(Billions of Yen)

																	Forecasts			
			FY2007	FY2008	FY2009				FY2010						FY2011					
			1-12	1-12	1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)	1-6	Change (%)	1-12	Change (%)
			Full-year	Full-year	YTD	YTD	YTD	YTD	YTD		YTD		YTD		YTD		Half-year		Full-year	
Sales			332.9	321.8	92.9	185.9	303.4	419.1	86.2	-7.2	180.6	-2.9	273.3	-9.9	375.6	-10.4	182.5	+1.1	391.7	+4.3
Excl. Tamiflu			294.3	313.4	72.5	160.6	247.6	342.9	75.4	+4.0	168.6	+5.0	257.4	+4.0	357.4	+4.2	176.8	+4.9	379.5	+6.2
Domestic			263.1	279.9	66.2	146.3	223.9	309.3	68.0	+2.7	150.6	+2.9	231.3	+3.3	324.4	+4.9	157.5	+4.6	340.8	+5.1
Oncology field			74.0	102.3	25.7	57.8	88.9	123.7	28.8	+12.1	64.6	+11.8	100.1	+12.6	141.2	+14.1	69.4	+7.4	153.5	+8.7
Avastin *1			3.5	20.1	6.7	15.4	24.3	34.9	10.3	+53.7	23.3	+51.3	36.8	+51.4	52.6	+50.7	28.8	+23.6	64.8	+23.2
Herceptin			16.1	23.7	6.6	14.7	22.0	29.7	5.7	-13.6	12.1	-17.7	18.3	-16.8	25.3	-14.8	11.8	-2.5	24.6	-2.8
Rituxan			18.6	20.5	4.3	9.7	15.1	21.1	4.5	+4.7	10.3	+6.2	16.1	+6.6	23.0	+9.0	10.5	+1.9	23.5	+2.2
Xeloda			2.7	4.8	1.3	2.8	4.4	6.6	2.3	+76.9	5.1	+82.1	7.8	+77.3	10.7	+62.1	5.0	-2.0	11.7	+9.3
Neutrogen			12.6	12.0	2.2	5.2	8.2	11.3	2.0	-9.1	4.6	-11.5	7.2	-12.2	10.4	-8.0	4.6	+0.0	10.4	+0.0
Tarceva *1			0.2	4.5	1.2	2.7	4.1	5.8	1.4	+16.7	3.5	+29.6	5.5	+34.1	7.9	+36.2	4.0	+14.3	8.8	+11.4
Kytril			13.6	10.9	2.1	4.5	6.6	8.6	1.5	-28.6	3.0	-33.3	4.3	-34.8	5.5	-36.0	1.8	-40.0	3.9	-29.1
Femara			1.0	1.7	0.5	1.1	1.7	2.4	0.6	+20.0	1.4	+27.3	2.2	+29.4	3.2	+33.3	1.7	+21.4	3.8	+18.8
Other products			5.6	4.1	0.8	1.7	2.5	3.3	0.6	-25.0	1.3	-23.5	1.9	-24.0	2.5	-24.2	1.0	-23.1	2.0	-20.0
Bone and joint diseases field			46.6	50.0	12.2	26.9	41.2	57.6	13.0	+6.6	28.6	+6.3	44.1	+7.0	62.6	+8.7	31.8	+11.2	68.8	+9.9
Evista			16.0	16.5	3.8	8.4	12.8	17.9	3.8	+0.0	8.6	+2.4	13.1	+2.3	18.7	+4.5	8.3	-3.5	17.5	-6.4
Actemra			0.5	3.4	1.5	3.5	5.7	8.4	2.6	+73.3	5.8	+65.7	9.4	+64.9	14.1	+67.9	9.6	+65.5	21.8	+54.6
Suvenyl			11.0	12.0	2.8	6.5	10.0	13.7	2.9	+3.6	6.4	-1.5	9.7	-3.0	13.6	-0.7	6.7	+4.7	14.4	+5.9
Alfarol			14.3	13.7	3.0	6.5	9.9	13.6	2.7	-10.0	5.9	-9.2	8.8	-11.1	12.3	-9.6	5.2	-11.9	11.1	-9.8
Other products			4.8	4.5	1.1	2.1	2.8	3.9	1.0	-9.1	1.9	-9.5	3.1	+10.7	4.0	+2.6	1.9	+0.0	4.0	+0.0
Renal diseases field			69.6	61.3	13.0	28.8	44.4	61.0	12.5	-3.8	27.2	-5.6	41.7	-6.1	57.4	-5.9	26.6	-2.2	56.7	-1.2
Epogin			54.8	44.9	9.4	20.8	32.3	44.4	8.7	-7.4	19.0	-8.7	29.2	-9.6	40.0	-9.9	18.5	-2.6	39.2	-2.0
Oxarol			8.7	10.0	2.2	4.9	7.7	10.6	2.5	+13.6	5.6	+14.3	8.6	+11.7	12.0	+13.2	5.7	+1.8	12.4	+3.3
Renagel			5.6	5.7	1.3	2.7	4.0	5.3	1.1	-15.4	2.3	-14.8	3.5	-12.5	4.9	-7.5	2.2	-4.3	4.6	-6.1
Other products			0.5	0.7	0.2	0.4	0.5	0.7	0.2	+0.0	0.3	-25.0	0.4	-20.0	0.5	-28.6	0.2	-33.3	0.5	+0.0
Transplant, Immunology & Infectious diseases field			17.7	24.0	5.9	12.8	19.3	26.2	5.3	-10.2	11.9	-7.0	18.3	-5.2	25.8	-1.5	11.6	-2.5	25.2	-2.3
Pegasys			6.3	9.7	2.5	5.5	8.2	11.1	2.2	-12.0	4.8	-12.7	7.4	-9.8	10.5	-5.4	4.9	+2.1	10.7	+1.9
Copegus *1			2.0	4.2	1.1	2.4	3.6	4.9	0.9	-18.2	2.0	-16.7	3.1	-13.9	4.5	-8.2	2.2	+10.0	4.7	+4.4
Rocephin			5.7	5.9	1.3	2.7	4.1	5.5	1.1	-15.4	2.6	-3.7	3.9	-4.9	5.4	-1.8	1.8	-30.8	3.7	-31.5
CellCept			3.5	4.0	0.9	2.1	3.2	4.4	1.0	+11.1	2.3	+9.5	3.6	+12.5	5.2	+18.2	2.7	+17.4	5.8	+11.5
Other products			0.3	0.3	0.1	0.1	0.2	0.3	0.1	+0.0	0.1	+0.0	0.2	+0.0	0.3	+0.0	0.1	+0.0	0.3	+0.0
Others field			55.1	42.3	9.4	20.0	30.1	40.9	8.3	-11.7	18.3	-8.5	27.1	-10.0	37.4	-8.6	18.0	-1.6	36.6	-2.1
Sigmart			15.2	15.0	3.3	7.1	10.6	14.7	2.9	-12.1	6.3	-11.3	9.4	-11.3	13.0	-11.6	6.2	-1.6	12.6	-3.1
SA products *2			11.2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other products			28.8	27.3	6.2	13.0	19.4	26.3	5.4	-12.9	12.0	-7.7	17.7	-8.8	24.4	-7.2	11.9	-0.8	24.0	-1.6
Overseas			31.2	33.5	6.3	14.2	23.7	33.6	7.4	+17.5	18.1	+27.5	26.1	+10.1	33.0	-1.8	19.3	+6.6	38.7	+17.3
Neutrogen			26.6	25.9	4.8	10.2	15.8	21.3	4.4	-8.3	8.8	-13.7	13.0	-17.7	17.0	-20.2	6.9	-21.6	13.6	-20.0
Actemra			-	3.8	0.4	1.8	5.1	8.9	2.0	+400.0	7.4	+311.1	10.5	+105.9	12.7	+42.7	10.5	+41.9	21.7	+70.9
Sigmart			2.8	2.0	0.6	1.3	1.5	1.9	0.8	+33.3	1.3	+0.0	1.8	+20.0	2.2	+15.8	1.3	+0.0	2.2	+0.0
Other products			1.9	1.7	0.5	1.0	1.2	1.5	0.2	-60.0	0.5	-50.0	0.8	-33.3	1.2	-20.0	0.7	+40.0	1.1	-8.3
Tamiflu			38.7	8.4	20.4	25.4	55.8	76.2	10.8	-47.1	12.0	-52.8	15.8	-71.7	18.2	-76.1	5.7	-52.5	12.2	-33.0
Ordinary sales			10.2	7.1	6.0	11.0	18.5	36.2	1.4	-76.7	1.4	-87.3	1.4	-92.4	1.6	-95.6	5.3	+278.6	7.8	+387.5
Govt. stockpile etc.			28.5	1.3	14.4	14.4	37.3	40.0	9.5	-34.0	10.6	-26.4	14.4	-61.4	16.6	-58.5	0.4	-96.2	4.4	-73.5
Other operating revenues			11.9	5.1	1.8	5.7	6.3	9.8	0.9	-50.0	1.7	-70.2	2.8	-55.6	3.9	-60.2	7.5	+341.2	11.3	+189.7
Revenues (total)			344.8	326.9	94.7	191.7	309.7	428.9	87.1	-8.0	182.4	-4.9	276.1	-10.8	379.5	-11.5	190.0	+4.2	403.0	+6.2
Domestic			308.4	293.1	86.7	175.5	283.7	392.6	78.9	-9.0	162.8	-7.2	247.5	-12.8	342.9	-12.7	166.6	+2.3	356.6	+4.0
Overseas			36.4	33.8	8.0	16.2	26.1	36.4	8.2	+2.5	19.6	+21.0	28.6	+9.6	36.6	+0.5	23.4	+19.4	46.5	+27.0

Notes: 1. The products marketed in 2007 and subsequent years are as follows: Avastin (launched in June 2007), Tarceva (December 2007), Copegus (March 2007).
2. Sales of the products for which the marketing collaboration in Japan with sanofi-aventis K.K. ended on December 31, 2007, are included in the "Others field (SA products)."

Statements of Revenues (QTR)

(Billions of Yen)

																	Forecasts					
			FY2007	FY2008	FY2009				FY2010						FY2011							
			1-12	1-12	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)	1-6	Change (%)	7-12	Change (%)		
			Full-year	Full-year	QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR		1st Half		2nd Half			
Sales			332.9	321.8	92.9	93.0	117.5	115.7	86.2	-7.2	94.5	+1.6	92.6	-21.2	102.3	-11.6	182.5	+1.1	209.2	+7.3		
	Excl. Tamiflu		294.3	313.4	72.5	88.1	87.0	95.3	75.4	+4.0	93.3	+5.9	88.8	+2.1	100.0	+4.9	176.8	+4.9	202.7	+7.4		
		Domestic	263.1	279.9	66.2	80.1	77.6	85.4	68.0	+2.7	82.6	+3.1	80.8	+4.1	93.0	+8.9	157.5	+4.6	183.4	+5.5		
			Oncology field	74.0	102.3	25.7	32.1	31.1	34.8	28.8	+12.1	35.7	+11.2	35.5	+14.1	41.1	+18.1	69.4	+7.4	84.2	+9.9	
			Avastin	3.5	20.1	6.7	8.6	8.9	10.6	10.3	+53.7	13.0	+51.2	13.5	+51.7	15.8	+49.1	28.8	+23.6	36.0	+22.4	
			Herceptin	16.1	23.7	6.6	8.1	7.3	7.7	5.7	-13.6	6.4	-21.0	6.2	-15.1	6.9	-10.4	11.8	-2.5	12.8	-2.3	
			Rituxan	18.6	20.5	4.3	5.5	5.4	5.9	4.5	+4.7	5.8	+5.5	5.8	+7.4	6.9	+16.9	10.5	+1.9	13.0	+2.4	
			Xeloda	2.7	4.8	1.3	1.5	1.6	2.2	2.3	+76.9	2.8	+86.7	2.7	+68.8	2.9	+31.8	5.0	-2.0	6.7	+19.6	
			Neutrogen	12.6	12.0	2.2	3.0	3.0	3.1	2.0	-9.1	2.6	-13.3	2.6	-13.3	3.3	+6.5	4.6	+0.0	5.8	-1.7	
			Tarceva	0.2	4.5	1.2	1.5	1.4	1.7	1.4	+16.7	2.0	+33.3	2.0	+42.9	2.4	+41.2	4.0	+14.3	4.8	+9.1	
			Kytril	13.6	10.9	2.1	2.4	2.1	2.1	1.5	-28.6	1.5	-37.5	1.3	-38.1	1.2	-42.9	1.8	-40.0	2.0	-20.0	
			Femara	1.0	1.7	0.5	0.6	0.6	0.7	0.6	+20.0	0.8	+33.3	0.8	+33.3	1.0	+42.9	1.7	+21.4	2.0	+11.1	
			Other products	5.6	4.1	0.8	0.9	0.8	0.8	0.6	-25.0	0.7	-22.2	0.6	-25.0	0.7	-12.5	1.0	-23.1	1.0	-23.1	
			Bone and joint diseases field	46.6	50.0	12.2	14.8	14.3	16.4	13.0	+6.6	15.7	+6.1	15.4	+7.7	18.5	+12.8	31.8	+11.2	37.0	+8.8	
			Evista	16.0	16.5	3.8	4.6	4.4	5.1	3.8	+0.0	4.8	+4.3	4.5	+2.3	5.6	+9.8	8.3	-3.5	9.2	-8.9	
			Actemra	0.5	3.4	1.5	2.0	2.2	2.7	2.6	+73.3	3.3	+65.0	3.6	+63.6	4.7	+74.1	9.6	+65.5	12.2	+48.8	
			Suvenyl	11.0	12.0	2.8	3.7	3.5	3.7	2.9	+3.6	3.5	-5.4	3.3	-5.7	3.9	+5.4	6.7	+4.7	7.6	+5.6	
			Alfarol	14.3	13.7	3.0	3.5	3.3	3.7	2.7	-10.0	3.2	-8.6	2.9	-12.1	3.5	-5.4	5.2	-11.9	5.9	-7.8	
			Other products	4.8	4.5	1.1	1.0	0.8	1.1	1.0	-9.1	0.9	-10.0	1.1	+37.5	0.9	-18.2	1.9	+0.0	2.0	+0.0	
			Renal diseases field	69.6	61.3	13.0	15.8	15.6	16.5	12.5	-3.8	14.7	-7.0	14.6	-6.4	15.6	-5.5	26.6	-2.2	30.0	-0.7	
			Epogin	54.8	44.9	9.4	11.5	11.4	12.1	8.7	-7.4	10.3	-10.4	10.2	-10.5	10.8	-10.7	18.5	-2.6	20.7	-1.4	
			Oxarol	8.7	10.0	2.2	2.8	2.7	2.9	2.5	+13.6	3.1	+10.7	3.0	+11.1	3.4	+17.2	5.7	+1.8	6.7	+4.7	
			Renagel	5.6	5.7	1.3	1.4	1.3	1.3	1.1	-15.4	1.2	-14.3	1.2	-7.7	1.3	+0.0	2.2	-4.3	2.4	-4.0	
			Other products	0.5	0.7	0.2	0.1	0.2	0.1	0.2	+0.0	0.1	+0.0	0.1	-50.0	0.1	+0.0	0.2	-33.3	0.2	+0.0	
			Transplant, Immunology & Infectious diseases field	17.7	24.0	5.9	6.9	6.5	6.8	5.3	-10.2	6.6	-4.3	6.4	-1.5	7.4	+8.8	11.6	-2.5	13.6	-2.2	
			Pegasys	6.3	9.7	2.5	2.9	2.8	2.9	2.2	-12.0	2.6	-10.3	2.6	-7.1	3.0	+3.4	4.9	+2.1	5.9	+3.5	
			Copegus	2.0	4.2	1.1	1.3	1.2	1.2	0.9	-18.2	1.1	-15.4	1.1	-8.3	1.3	+8.3	2.2	+10.0	2.5	+4.2	
			Rocephin	5.7	5.9	1.3	1.5	1.4	1.4	1.1	-15.4	1.5	+0.0	1.4	+0.0	1.5	+7.1	1.8	-30.8	1.9	-32.1	
			CellCept	3.5	4.0	0.9	1.1	1.1	1.2	1.0	+11.1	1.3	+18.2	1.3	+18.2	1.5	+25.0	2.7	+17.4	3.1	+10.7	
			Other products	0.3	0.3	0.1	0.1	0.1	0.1	0.1	+0.0	0.1	+0.0	0.1	+0.0	0.1	+0.0	0.1	+0.0	0.1	-50.0	
			Others field	55.1	42.3	9.4	10.6	10.0	10.9	8.3	-11.7	9.9	-6.6	8.8	-12.0	10.3	-5.5	18.0	-1.6	18.6	-3.1	
			Sigmat	15.2	15.0	3.3	3.8	3.6	4.0	2.9	-12.1	3.4	-10.5	3.0	-16.7	3.7	-7.5	6.2	-1.6	6.4	-4.5	
			SA products	11.2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
			Other products	28.8	27.3	6.2	6.8	6.5	6.8	5.4	-12.9	6.5	-4.4	5.8	-10.8	6.7	-1.5	11.9	-0.8	12.2	-2.4	
			Overseas	31.2	33.5	6.3	7.9	9.5	9.9	7.4	+17.5	10.7	+35.4	8.0	-15.8	6.9	-30.3	19.3	+6.6	19.4	+29.3	
				Neutrogen	26.6	25.9	4.8	5.4	5.6	5.5	4.4	-8.3	4.4	-18.5	4.2	-25.0	4.0	-27.3	6.9	-21.6	6.7	-18.3
				Actemra	-	3.8	0.4	1.4	3.3	3.8	2.0	+400.0	5.4	+285.7	3.1	-6.1	2.2	-42.1	10.5	+41.9	11.2	+111.3
				Sigmat	2.8	2.0	0.6	0.6	0.3	0.4	0.8	+33.3	0.6	+0.0	0.4	+33.3	0.4	+0.0	1.3	+0.0	1.0	+11.1
				Other products	1.9	1.7	0.5	0.5	0.2	0.2	0.2	-60.0	0.3	-40.0	0.3	+50.0	0.3	+50.0	0.7	+40.0	0.5	-16.7
			Tamiflu	38.7	8.4	20.4	5.0	30.4	20.4	10.8	-47.1	1.2	-76.0	3.8	-87.5	2.3	-88.7	5.7	-52.5	6.5	+6.6	
				Ordinary sales	10.2	7.1	6.0	5.0	7.6	17.7	1.4	-76.7	0.0	-100.0	0.0	-98.9	5.3	+278.6	2.5	+1,150.0		
				Govt. stockpile etc.	28.5	1.3	14.4	-	22.9	2.7	9.5	-34.0	1.2	-	3.8	-83.4	2.1	-22.2	0.4	-96.2	4.0	-32.2
Other operating revenues			11.9	5.1	1.8	4.0	0.5	3.6	0.9	-50.0	0.8	-80.0	1.1	+120.0	1.1	-69.4	7.5	+341.2	3.8	+72.7		
Revenues (total)			344.8	326.9	94.7	97.0	118.0	119.2	87.1	-8.0	95.3	-1.8	93.7	-20.6	103.4	-13.3	190.0	+4.2	213.0	+8.1		
		Domestic	308.4	293.1	86.7	88.8	108.1	108.9	78.9	-9.0	83.9	-5.5	84.7	-21.6	95.5	-12.3	166.6	+2.3	190.0	+5.5		
		Overseas	36.4	33.8	8.0	8.2	9.9	10.3	8.2	+2.5	11.4	+39.0	9.0	-9.1	8.0	-22.3	23.4	+19.4	23.0	+35.3		

Balance Sheets

(Billions of Yen)

	FY2007	FY2008	FY2009				FY2010				
	As of Dec. 31	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	vs. Dec. 31, 2009
Cash and deposits	73.2	70.8	77.6	90.8	77.6	107.0	101.1	81.3	70.2	76.2	-30.8
Trade notes and accounts receivable	107.0	108.5	111.3	102.7	121.8	121.6	85.4	99.2	99.3	113.4	-8.2
Marketable securities	65.5	54.7	46.0	54.5	55.6	52.2	55.7	61.7	58.7	59.7	7.5
Inventories	55.2	78.7	78.7	94.0	90.4	92.6	100.0	111.7	115.9	104.9	12.3
Other current assets	28.9	31.7	34.3	30.9	32.3	37.9	41.7	29.5	35.0	32.3	-5.6
Total Current assets	329.8	344.4	347.9	372.9	377.7	411.3	383.9	383.4	379.1	386.5	-24.8
Property, plant and equipment	92.5	98.3	97.1	96.2	93.7	93.7	91.4	89.8	88.4	88.0	-5.7
Intangible assets	3.7	3.1	3.2	3.0	2.7	3.2	3.0	2.6	2.6	2.4	-0.8
Investments and other assets	32.9	32.7	30.6	29.6	31.2	32.3	32.9	31.4	31.1	31.2	-1.1
thereof Investment securities	16.8	14.4	11.8	10.6	9.8	9.7	9.5	8.0	7.3	7.6	-2.1
Total Noncurrent Assets	129.1	134.2	130.9	128.8	127.6	129.2	127.2	123.8	122.1	121.5	-7.7
Total Assets	458.9	478.5	478.7	501.7	505.3	540.5	511.1	507.2	501.2	508.0	-32.5
Trade notes and accounts payable	17.3	28.8	34.0	37.8	34.3	34.3	35.4	32.2	26.2	19.5	-14.8
Short-term loans and bonds	0.3	-	-	-	-	-	-	-	-	-	-
Other current liabilities	52.1	49.8	41.4	44.7	49.0	66.2	42.2	36.3	33.2	35.1	-31.1
Total current liabilities	69.8	78.5	75.4	82.5	83.3	100.5	77.6	68.5	59.4	54.6	-45.9
Long-term debt and bonds	-	-	-	-	-	-	-	-	-	-	-
Other noncurrent liabilities	3.3	2.9	3.0	3.3	3.6	5.4	5.2	4.8	5.0	4.0	-1.4
Total noncurrent liabilities	3.3	2.9	3.0	3.3	3.6	5.4	5.2	4.8	5.0	4.0	-1.4
Total liabilities	73.1	81.5	78.4	85.8	86.9	105.9	82.8	73.3	64.4	58.6	-47.3
Common stock	72.9	73.0	73.0	73.0	73.0	73.0	73.0	73.0	73.0	73.0	-
Additional paid-in capital	92.8	92.8	92.8	92.8	92.8	92.8	92.8	92.8	92.8	92.8	-
Retained earnings	248.1	271.0	274.4	286.9	292.3	308.0	303.3	311.8	314.3	327.6	19.6
Treasury stock, at cost	-35.1	-35.2	-35.2	-35.2	-36.3	-36.3	-36.3	-36.3	-36.3	-36.3	0.0
Net unrealized gain on securities	2.8	1.4	0.9	2.0	1.7	1.6	1.8	1.5	1.2	1.3	-0.3
Foreign currency translation adjustments	1.9	-7.9	-7.3	-5.8	-6.9	-6.8	-8.2	-11.1	-10.1	-11.3	-4.5
New share warrants	0.1	0.3	0.4	0.4	0.5	0.5	0.6	0.6	0.7	0.8	0.3
Minority interests	2.2	1.7	1.3	1.8	1.4	1.8	1.3	1.4	1.2	1.4	-0.4
Total net assets	385.8	397.1	400.4	416.0	418.4	434.7	428.4	433.9	436.7	449.4	14.7
Total liabilities and net assets	458.9	478.5	478.7	501.7	505.3	540.5	511.1	507.2	501.2	508.0	-32.5

Cash Flows

(Billions of Yen)

	FY2007	FY2008	FY2009				FY2010			
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12
	Full-year	Full-year	YTD	YTD	YTD	Full-year	YTD	YTD	YTD	Full-year
Net cash provided by (used in) operating activities	60.4	39.3	13.0	33.7	36.9	66.5	16.4	6.8	4.4	15.6
Net cash provided by (used in) investing activities	-7.5	-14.1	-3.9	-13.3	-21.6	-20.3	1.2	-16.6	-16.2	-20.2
Net cash provided by (used in) financing activities	-47.2	-18.4	-11.0	-11.0	-22.3	-22.3	-13.2	-13.2	-23.1	-23.1
Effect of exchange rate changes on cash and cash equivalents	-0.3	-9.9	-0.6	0.6	1.0	-0.1	-0.6	-1.5	-1.2	-1.7
Net increase (decrease) in cash and cash equivalents	5.4	-3.1	-2.5	9.9	-6.1	23.8	3.8	-24.5	-36.1	-29.3
Cash and cash equivalents at beginning of period	68.3	73.7	70.7	70.7	70.7	70.7	94.5	94.5	94.5	94.5
Cash and cash equivalents at end of period	73.7	70.7	68.1	80.6	64.6	94.5	98.2	69.9	58.4	65.1

Performance Indicators

	FY2007	FY2008	FY2009				FY2010				Forecast
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	FY2011
	As of Dec. 31	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Dec. 31
Net income per share (Basic)	73.23yen	72.07yen	25.27yen	48.29yen	75.07yen	104.00yen	14.43yen	30.09yen	51.55yen	76.14yen	78.10yen
Net income per share (Fully diluted)	73.16yen	72.04yen	25.27yen	48.28yen	75.06yen	103.98yen	14.43yen	30.09yen	51.54yen	76.12yen	-
Return on equity (ROE)*	10.4%	10.1%	3.5%	6.5%	10.1%	13.7%	1.8%	3.8%	6.5%	9.4%	-
Return on assets (ROA)*	14.7%	12.2%	4.8%	8.9%	13.4%	17.7%	2.3%	5.0%	8.5%	12.4%	-
Net assets per share	703.80yen	725.18yen	731.74yen	759.41yen	765.47yen	794.51yen	783.67yen	793.50yen	799.11yen	821.87yen	-
Equity ratio	83.5%	82.6%	83.3%	82.5%	82.4%	80.0%	83.4%	85.1%	86.8%	88.0%	-
Dividends per share (Annual)	30yen	34yen				40yen				40yen	40yen
Dividends per share (Interim)	15yen	15yen				17yen				17yen	20yen
Payout ratio	41.0%	47.2%				38.5%				52.5%	51.2%

Note: Quarterly (year-to-date) ROE and ROA are not annualized.

Number of Employees

	FY2007	FY2008	FY2009				FY2010				Forecast
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	FY2011
	As of Dec. 31	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Dec. 31
Number of employees	6,257	6,383	6,347	6,474	6,481	6,485	6,472	6,707	6,723	6,709	6,830

Note: Number of employees doesn't include staff seconded to companies outside the Group.

Capital Expenditures

(Billions of Yen)

	FY2007	FY2008	FY2009				FY2010				Forecast
	1-12	1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	FY2011
	Full-year	Full-year	YTD	YTD	YTD	Full-year	YTD	YTD	YTD	Full-year	Full-year
Capital expenditures	19.6	26.6	2.8	6.6	9.1	14.6	1.8	4.6	7.9	12.7	14.0
Depreciation	13.3	19.4	4.2	8.9	14.1	19.5	4.1	8.4	13.0	18.0	17.0

Major Capital Investments Plan

(The Company)

None

(Domestic Subsidiaries)

None

Commitment Line (Loan Framework) Contract

(Billions of Yen)

	Amount
Total Commitments	40.0
Commitments used	—
Commitments unused	40.0

Note: The Company maintains commitment line contracts with ten financial institutions.

Development pipeline (as of February 2, 2011)

Development code	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
<u>Oncology</u>					
RG435	Breast cancer #	Filed Oct. 09	bevacizumab Avastin Injection	Roche Avastin	Humanized anti-VEGF(Vascular Endothelial Growth Factor) monoclonal antibody
	Gastric cancer #	Phase III Multinational study			
	Breast cancer (adjuvant) #	Phase III Multinational study			
	Glioblastoma #	Phase III Multinational study			
	Glioblastoma (relapsed) #	Phase II			
	Colon cancer (adjuvant) #	Development suspended			
EPOCH	Chemotherapy-induced anemia #	Filed Nov. 09	epoetin beta Epogin Injection	In-house	Recombinant human erythropoietin
RG340	Gastric cancer #	Filed Sep. 10	capecitabine Xeloda Oral	Roche Xeloda	Antimetabolite, 5-FU derivative
RG597	Gastric cancer #	Filed Mar. 10	trastuzumab Herceptin Injection	Roche Herceptin	Humanized anti-HER2 monoclonal antibody
RG1415	Pancreatic cancer #	Filed Sep. 09	erlotinib Tarceva Oral	Roche/OSI Tarceva	EGFR tyrosine kinase inhibitor
	Non-small cell lung cancer (1st line) #	Phase II			
RG1273	Breast cancer	Phase III Multinational study	pertuzumab Injection	Roche	Humanized HER dimerization inhibitory monoclonal antibody
RG3502	Breast cancer	Phase II	Injection	Roche	HER2 antibody-drug conjugate (T-DM1)

Development code	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
TP300	Gastric cancer, etc	Phase II Overseas	Injection	In-house	Topoisomerase I inhibitor
MRA	Pancreatic cancer #	Phase I / II	tocilizumab Actemra Injection	In-house (Roche)	Humanized anti-human IL-6 receptor monoclonal antibody
AF802	Non-small cell lung cancer	Phase I / II	Oral	In-house	ALK inhibitor
WT4869	Myelodysplastic syndromes	Phase I / II	Injection	In-house / Dainippon Sumitomo Pharma	WT1 peptide cancer vaccine
CIF (RG7167)	Solid tumors	Phase I	Oral	In-house	MEK inhibitor
		Phase I Overseas		(Roche)	
CKI27 (RG7304)	Solid tumors	Phase I	Oral	In-house	Raf and MEK dual inhibitor
		Phase I Overseas		(Roche)	
GC33	Liver cancer	Phase I	Injection	In-house	Humanized anti-Glypican-3 monoclonal antibody
		Phase I Overseas		(Roche)	
PA799	Solid tumors	Phase I Overseas	Oral	In-house	-
GA101 (RG7159)	Non-Hodgkin's lymphoma	Phase I	Injection	Roche	Humanized anti-CD20 monoclonal antibody
<u>Bone and Joint diseases</u>					
ED-71	Osteoporosis	Approved Jan. 11	eldecalcitol Edirol Oral	In-house (Taisho Pharmaceutical)	Active Vitamin D ₃ derivative

Development code	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
MRA	Systemic onset juvenile idiopathic arthritis (sJIA) #	Filed Oct. 10 Overseas	tocilizumab Actemra / RoActemra(EU) Injection	In-house (Roche)	Humanized anti-human IL-6 receptor monoclonal antibody
	Rheumatoid arthritis (new formulation: subcutaneous injection)	Phase III			
		Phase III Overseas			
RG484	Osteoporosis	Phase II / III	ibandronate sodium hydrate Injection	Roche Boniva (US) / Bonviva (EU) (Taisho Pharmaceutical)	Bisphosphonate
		Phase II	ibandronate sodium hydrate Oral		
SA237	Rheumatoid arthritis	Phase I	Injection	In-house	Humanized anti-human IL-6 receptor monoclonal antibody
Renal diseases					
RG744	Renal anemia	Filed Jul. 09	Epoetin beta pegol Mircera Injection	Roche Mircera	Continuous erythropoietin receptor activator
Transplant, Immunology and Infectious diseases					
RG964	Compensated liver cirrhosis caused by hepatitis C virus #	Filed Oct. 10	ribavirin Copegus Oral	Roche Copegus	Anti-viral agent, in combination with Pegasys
RG442	Chronic hepatitis B #	Filed Jan. 11	peginterferon alfa-2a Pegasys Injection	Roche Pegasys	Peginterferon alfa-2a agent (recombinant)
NA808	Chronic hepatitis C	Development suspended	Injection	In-house	Serine palmitoyltransferase inhibitor
Other diseases					
CSG452 (RG7201)	Type II diabetes	Phase III	tofogliflozin Oral	In-house (Roche)	SGLT2 inhibitor

Development code	Indication # Additional indication	Stage (date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
RG1678	Schizophrenia	Phase III Multinational study	Oral	Roche	GLYT1 inhibitor
RG1583 (ITM-077)	Type II diabetes	Phase II	taspoglutide Injection	Roche/Ipsen (Teijin)	GLP-1 analogue
RG1450	Alzheimer's disease	Phase I	gantenerumab Injection	Roche/Morphosys	Human anti-amyloid-beta monoclonal antibody

Changes from the last announcement on October 22, 2010

Oncology

-RG435 Phase III → Development suspended (Colon cancer (adjuvant))
 -WT4869 Phase I/II (Myelodysplastic syndromes)
 -GC33 Phase I (Liver cancer: Japan)

Bone and Joint diseases

-ED-71 Filed → Approved (Osteoporosis)
 -SA237 Phase I (Rheumatoid arthritis)

Transplant, Immunology and Infectious diseases

-RG964/RG442 Phase II/III → Filed (Compensated liver cirrhosis caused by hepatitis C virus)
 -RG442 Phase II/III → Filed (Chronic hepatitis B)
 -NA808 Phase I → Development suspended (Chronic hepatitis C)

Other diseases

-CSG452 Phase II multinational study → Phase III (Type II diabetes)
 -RG1678 Phase II multinational study → Phase III multinational study (Schizophrenia)

R&D Activities (Jan. 1, 2010 – Feb. 2, 2011)

As for clinical development activities in Japan, the Company saw progress as described below:

Oncology

- We decided to suspend our development of a humanized anti-VEGF monoclonal antibody, RG435 (product name: Avastin, expected indication: colon cancer (adjuvant)), following the fact that results from a Phase III multinational study conducted by Roche did not meet primary endpoint.
- In March 2010, we filed an application for an additional indication of combination therapy with a 5-FU derivative, RG340 (product name: Xeloda), and a humanized anti-HER2 monoclonal antibody, RG597 (product name: Herceptin), for gastric cancer. In September 2010, we filed an “NDA based on evidence in the public domain” for RG340 (product name: Xeloda), for gastric cancer in a result that the “Review Committee on Unapproved Drugs and Indications with High Medical Needs” concluded this process is applicable.
- In April 2010, we started a Phase II trial (expected indication: non-small cell lung cancer [1st line]) for an EGFR tyrosine kinase inhibitor, RG1415 (product name: Tarceva).
- In October 2010, we started a Phase II trial (expected indication: breast cancer) for a HER2 antibody-drug conjugate, RG3502.
- In September 2010, we started a Phase I/II trial (expected indication: non-small cell lung cancer) for an ALK inhibitor, AF802.
- In February 2011, we will start a Phase I/II trial (expected indication: myelodysplastic syndromes) for a WT1 peptide cancer vaccine, WT4869.
- In January 2010, we started a Phase I trial (expected indication: solid tumors) for a Raf and MEK dual inhibitor, CKI27 (RG7304).
- In October 2010, we started a Phase I trial (expected indication: liver cancer) for a humanized anti-Glypican-3 monoclonal antibody, GC33.

Bone and Joint diseases

- In January 2011, we obtained an approval for an active Vitamin D3 derivative, ED-71 (product name: Ediol), for osteoporosis.
- In May 2010, we started a Phase III trial (new formulation: subcutaneous injection) for a humanized anti-human IL-6 receptor monoclonal antibody, MRA (product name: Actemra).
- After re-evaluating risk/benefit balance, we have decided to suspend our development of a humanized anti-CD20 monoclonal antibody, RG1594 for rheumatoid arthritis.
- In December 2010, we started a Phase I trial (expected indication: Rheumatoid arthritis) for a humanized anti-human IL-6 receptor monoclonal antibody, SA237.

Transplant, Immunology and Infectious Diseases

- In October 2010, we filed an application for an additional indication of an anti-viral agent, RG964 (product name: Copegus), in combination with a peginterferon alfa-2a agent (recombinant), RG442 (product name: Pegasys), for compensated liver cirrhosis caused by hepatitis C virus.
- In January 2011, we filed an application for an additional indication of a peginterferon alfa-2a agent (recombinant), RG442 (product name: Pegasys), for chronic hepatitis B.
- We decided to suspend our development for a serine palmitoyltransferase inhibitor, NA808 (expected indication: Chronic hepatitis C), following the fact that the results did not meet the efficacy criteria to proceed, though the results shows decrease of HCV viral load in a PI trial with chronic hepatitis C patients.
- After re-evaluating the allocation of resources to ongoing development programs, we have decided to discontinue our development of nitazoxanide for chronic hepatitis C. Romark Laboratories will continue development of nitazoxanide for chronic hepatitis C in Japan as part of its worldwide development program.

Other Diseases

- In June 2010, we obtained an approval for an additional indication of a recombinant human erythropoietin, EPOCH (product name: Epogin), for predeposit of autologous blood transfusion.
- In November 2010, we started a Phase III trial (expected indication: Type II diabetes) for a SGLT2 inhibitor, CSG452 (RG7201).
- In January 2011, we started a Phase III multinational study (expected indication: Schizophrenia) for a GLYT1 inhibitor, RG1678.

At present, we are awaiting the approvals of applications (new molecular entities or additions of indications) filed for 9 development themes, including RG435 (expected indication: breast cancer).

Also, as for development activities overseas, the Company saw progress as described below.

- In August 2010, we started a Phase I trial (expected indication: solid tumor) for PA799.
- In January 2010, Roche obtained an approval for a humanized anti-human IL-6 receptor monoclonal antibody, MRA (product name: Actemra), for rheumatoid arthritis from the U.S. Food & Drug Administration (FDA).
In September, Roche started a Phase III trial (new formulation: subcutaneous injection) for MRA for rheumatoid arthritis. In October, Roche filed an application for MRA for systemic onset juvenile idiopathic arthritis (sJIA).

Major clinical trials in oncology field currently running in Japan

Theme	Expected Indication	Regimen	Stage	Planned Filing Date
RG435 (bevacizumab) Avastin	Breast	paclitaxel + RG435	Filed (Oct. 09)	-
	Breast (adjuvant)	standard chemotherapy ± RG435	BEATRICE study : Phase III Multinational study	2014 2016
	Glioblastoma	temozolomide ± RG435	Phase III Multinational study	2014 2016
	Glioblastoma [relapsed]	RG435	Phase II	2014 2016
RG1415 (erlotinib) Tarceva	Pancreatic	gemcitabine + RG1415	Filed (Sep. 09)	-
RG597 (trastuzumab) Herceptin	Gastric	RG340 / 5FU + CDDP ± RG597	Filed (Mar. 10)	-
RG340 (capecitabine) Xeloda			Filed (Sep. 10)	
RG1273 (pertuzumab)	Breast	RG597 + docetaxel ± RG1273	CLEOPATRA study : Phase III Multinational study	2012
RG3502 (T-DM1)	Breast	RG3502	Phase II	2013